Enteric Disease Testing Market Report 2025

The enteric disease testing market size has grown strongly in recent years. It will grow from $4.62 billion in 2024 to $4.87 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to water and food safety concerns, increased outbreaks and epidemics, globalization of food supply, increased travel-related infections, regulatory standards.

The enteric disease testing market size is expected to see strong growth in the next few years. It will grow to $6.29 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to integration of telemedicine and remote monitoring, climate change effects, cross-sector collaboration, antimicrobial resistance, emerging enteric pathogens. Major trends in the forecast period include molecular diagnostics, digital health integration, ai and machine learning, adoption of syndromic testing, point-of-care testing.

The anticipated rise in cases of diarrhea and hemolytic urea syndrome (HUS) is poised to drive the growth of the enteric disease testing market. Diarrheal diseases, often caused by consuming contaminated food and water, are a significant health concern globally. Additionally, HUS, a disorder impacting blood and blood vessels, particularly in children with diarrhea, further contributes to the demand for testing solutions. According to the Centers for Disease Control and Prevention, diarrhea ranks as the second leading cause of mortality among children under the age of 5, resulting in 801 thousand deaths annually, making up one out of every nine child deaths. As these enteric diseases continue to prevail, the market for enteric disease testing is expected to witness growth.

The increasing consumption of frozen food is anticipated to drive the growth of the enteric disease testing market in the future. Frozen food is defined as food that has been preserved by lowering its temperature below freezing point, typically 0°F (-18°C), to extend its shelf life. However, frozen food can sometimes be a source of foodborne illnesses, including enteric diseases, due to improper handling, storage, or cooking. For example, in January 2023, the American Frozen Food Institute, a U.S.-based trade association for the frozen food industry, reported an 8.6% increase in frozen food sales in 2022, reaching $72.2 billion. Consequently, the rising consumption of frozen food products is fueling the growth of the enteric disease testing market.

Leading companies in the enteric disease testing market are concentrating on developing advanced diagnostic solutions, including laboratory tools, to enhance diagnostic accuracy and improve patient outcomes. Laboratory tools are specialized instruments and equipment utilized in scientific and medical laboratories to conduct tests, analyze samples, and generate precise data for diagnostics. These tools are crucial for improving the accuracy of diagnostic procedures and supporting research across various fields, including enteric disease testing. For example, in March 2023, Jiangsu Bioperfectus Technologies Co., Ltd., a biotechnology company based in China, introduced real-time PCR kits specifically designed for diagnosing gastrointestinal infectious diseases. These kits provide high sensitivity and specificity, allowing for the accurate detection of low levels of nucleic acids in various samples. They also facilitate rapid analysis, significantly reducing processing times and increasing throughput in diagnostic and research applications.

Leading companies in the enteric disease testing market are strategically focusing on the development of products capable of simultaneously measuring multiple biomarkers, aiming to gain a competitive advantage. The significance of enteric disease testing devices that can concurrently assess multiple biomarkers lies in their ability to diagnose and monitor various gastrointestinal conditions, ultimately enhancing patient care. A notable example is Quansys Biosciences Inc., which, in collaboration with the global health organization PATH, introduced the Q-Plex Human Environmental Enteric Dysfunction (11-Plex) diagnostic tool in July 2021. Designed to expedite interventions for Environmental Enteric Dysfunction (EED), this tool utilizes a chemiluminescent assay to simultaneously assess eleven biomarkers or analytes. It proves instrumental in researching and managing EED, offering an economical solution for profiling nutritional and inflammatory biomarkers associated with the condition.

In August 2022, SSI Diagnostica Group, a leading Nordic manufacturing, distribution, and technical service company based in Denmark, acquired TechLab, Inc. for an undisclosed sum. This acquisition is intended to help SSI Diagnostica Group expand its product offerings in infectious disease diagnostics, accelerate growth in the U.S. market, enhance its research and development capabilities, and strengthen its global operational presence. TechLab, Inc., a manufacturing company located in the U.S., specializes in developing and producing diagnostic tests specifically aimed at enteric pathogens.

Major companies operating in the enteric disease testing market include Becton Dickinson and Company, Biomerica Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Cepheid Inc., Coris Bioconcept, DiaSorin Molecular LLC, MMeridian Life Science Inc., Trinity Biotech plc., Abbott Laboratories, Fisher Scientific Inc., Alere Inc., 3M Company., Asure Quality, Bureau Veritas, Meridian Bioscience Inc., Hologic Inc., Luminex Corporation, Nanosphere Inc., Quidel Corporation, Roche Diagnostics, Siemens Healthcare Diagnostics Inc., Vela Diagnostics, GenMark Diagnostics, BioFire Diagnostics LLC, Veredus Laboratories Pte Ltd.

Enteric disease testing is essential for diagnosing diseases affecting the gastrointestinal tract, often caused by microorganisms such as viruses, bacteria, and parasites. These diseases, transmitted through contaminated food, water, or contact with infected individuals or animals, can lead to symptoms like abdominal cramping, vomiting, nausea, and anorexia, resulting in fluid and nutrient loss. Enteric disease testing employs various technologies, including diagnostic assays, rapid tests, stool specimen testing, complete blood count (CBC), blood culture tests, urine tests, antibody tests, and bone marrow tests to identify the causative agent.

The primary types of enteric diseases include bacterial enteric diseases, parasitic enteric diseases, viral enteric diseases, and others. Bacterial pathogens such as Salmonella, Campylobacter, Shigella, Clostridium difficile, and various strains of E. coli are common contributors to enteric diseases. Different testing technologies, including traditional methods, rapid tests, convenience-based tests, polymerase chain reaction (PCR), immunoassays, chromatography, spectrometry, and others, are employed for accurate diagnosis. These tests are conducted in various healthcare settings, including hospitals, research centers, clinics, and other medical facilities.

The enteric disease testing market research report is one of a series of new reports that provides enteric disease testing market statistics, including enteric disease testing industry global market size, regional shares, competitors with a enteric disease testing market share, detailed enteric disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the enteric disease testing industry. This enteric disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the enteric disease testing market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the global enteric disease testing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the enteric disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The enteric disease testing market includes revenues earned by entities by amebiasis, campylobacteriosis, cryptosporidiosis, and cyclosporiasis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.